Glenmark Pharmaceuticals’ wholly-owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is all set to launch of Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials, in March 2026.
Glenmark’s Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL and 45 mmol P / 66 mEq K per 15 mL Single-Dose Vials and 150 mmol P / 220 mEq K per 50 mL Pharmacy Bulk Package Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Potassium Phosphates Injection USP, 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL of Fresenius Kabi.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: